Prevention
Cardiovascular Disease, Cancer and Orthopaedics
At DeBartolo Longevity University, our commitment to prevention is exemplified by our innovative approach to bridging medical specialties. Our Cardiac Society for Bridging Medical Silos was founded on the principle of preventing major cardiac complications through collaboration between various fields of medicine, research, and industry.
One notable initiative is our cardio-orthopaedics society, which integrates cardiology with orthopaedics to mitigate the risk of cardiac complications during or after elective joint replacement surgeries. This program, currently active with our partners at the Florida Orthopaedics Institute, has also led to the development of our comprehensive textbook on the subject. As we continue to expand, we aim to extend this pioneering program nationwide, ensuring broader access to preventive care that spans multiple medical disciplines. For more information, visit Cardio-Orthopaedics.com.
New Blood Tests and New Imaging
One of our key tools for prevention is our partner company, Smartscan. This innovative screening tool, accessible to everyone, uses noninvasive CT scanning to detect cardiac calcium deposition, providing a lifesaving initial assessment for asymptomatic individuals concerned about their heart health. This is followed by a protocol for a CCTA (with contrast), which offers a more comprehensive analysis by detecting not only calcium but also “soft plaque,” stenosis, and other morphological changes. In collaboration with our affiliate Caristo, which offers the world’s leading cardiac AI fat attenuation index analysis, we are equipped to save lives even before patients realize they are at risk.
Our preventive approach extends beyond cardiac health. We screen for a wide range of common and rare diseases and disorders, covering everything from psychology to podiatry, to prevent major health issues and enhance the quality of life. We partner with multiple tumor marker screening services like GRAIL Galleri and Cologuard to detect potential cancer problems early. Additionally, our full-body scan protocols provide comprehensive health assessments, ensuring peace of mind for our members and their loved ones. Our Cardio-Oncology program, developed with prevention and treatment in mind, supports patients who have undergone heart-toxic chemotherapy, offering therapies to protect and improve cardiac health. For more information, visit IC-OS.org.
Initial and Periodic Follow-Up Review by Our Experts
During the initial encounter, we conduct a comprehensive evaluation of each individual, considering their entire medical history from birth to present, and assessing their health from head to toe. This thorough analysis allows us to create personalized treatment pathways tailored to each patient’s unique needs. Our goal is to establish accurate diagnoses and develop state-of-the-art therapeutics that are both preventative and curative. We aim not only to treat acute conditions but also to manage chronic issues and prevent potential complications, ensuring the best possible outcomes.
We offer regular follow-ups—whether weekly, monthly, bi-annually, or as needed—via telemedicine, phone calls, or in-person visits to ensure the stability and continuity of each patient’s healthcare.
In addition, we practice patient advocacy by referring “last-resort” or “forsaken” patients to the world’s best experts and specialists for life-saving and quality of life-preserving procedures and care. Many patients come to us when their own doctors have given up on them, and we take pride in our ability to provide them with hope and effective treatment.
New Medical Studies, Drugs, and Devices Researched and Reviewed Daily
At DeBartolo Longevity University, staying at the forefront of medical innovation is crucial to our mission of extending and enhancing life. We continuously research and review the latest medical studies, drugs, and devices to ensure that our patients have access to the most advanced and effective treatments available. By integrating cutting-edge technologies and breakthroughs into our practice, we can provide comprehensive, state-of-the-art care that addresses both current health issues and potential future risks. Here are some of the key technologies and innovations we utilize:
- VitalConnect: VitalConnect offers advanced biosensor technology for real-time health monitoring, providing crucial data for proactive health management.
- Stem Cell AUREGENs: AUREGENs leverages the power of stem cells for regenerative medicine, offering groundbreaking treatments for various conditions.
- Elucid: Elucid uses AI to provide detailed insights into cardiovascular health, aiding in precise diagnosis and treatment planning.
- Caristo: Caristo specializes in cardiac AI fat attenuation index analysis, enhancing the accuracy of cardiovascular risk assessments.
- Anumana: Anumana integrates AI into cardiac care, enabling early detection and intervention for heart conditions.
- Noninvasive Hemoglobin Monitoring: Masimo provides noninvasive hemoglobin monitoring technology, ensuring accurate and painless blood assessments.
- Canon Medical Advanced Imaging AI Vitrea: Vitrea offers advanced imaging solutions powered by AI, improving diagnostic precision.
- NICAS: NICAS delivers innovative cardiovascular diagnostic solutions, enhancing patient assessment and care.
- Smartheart EKG: Smartheart offers portable, high-quality EKG monitoring, making cardiac assessments more accessible and convenient.
- Exact Sciences: Exact Sciences specializes in early cancer detection technologies, helping to identify cancer risks before symptoms appear.
- Heartsee: Heartsee provides advanced cardiac PET imaging, offering detailed views of heart health for better diagnostic accuracy.
Technology Spotlight: Caristo
We are the only cardiologists in the USA utilizing Caristo’s advanced CCTA software to detect inflammation in individuals with normal or near-normal coronary arteries. This inflammation is a crucial early warning sign for 66% of those at risk of heart attack and sudden death within ten years. By identifying this risk early, we can prevent potential heart attacks by prescribing low-dose colchicine, a prevention method unique to Caristo’s technology.
Inflammation in the fat around the coronaries can be detected by the Caristo software and alerts us to the fact that 2/3 of patients with normal CCTAs are not “normal “ but at risk of a heart attack and sudden death! – The Lancet
We are the only cardiologists in the USA using Caristo’s advanced CCTA software since 2019 to detect inflammation in patients with normal or near-normal coronary arteries, which is a critical early warning sign for heart attacks and sudden death.
Unfortunately, many doctors in the USA focus on treating lower-risk obstructive arteries due to the fee-for-service model, leading to slow adoption of this life-saving technology. Our success hinges on raising public awareness through articles in the lay press, as this method is not yet FDA-approved in the USA.